Factors associated with failure to correct the international normalised ratio following fresh frozen plasma administration among patients treated for warfarin-related major bleeding

Summary

This study assessed the frequency and factors associated with failure to correct international normalised ratio (INR) in patients administered fresh frozen plasma (FFP) for warfarin-related major bleeding. This retrospective database analysis used electronic health records from an integrated health system. Patients who received FFP between 01/01/2004 and 01/31/2010, and who met the following criteria were selected: major haemorrhage diagnosis the day before to the day after initial FFP administration; INR ≥2 on the day before or the day of FFP and another INR result available; warfarin prescription within 90 days. INR correction (defined as INR ≤1.3) was evaluated at the last available test up to one day following FFP. A total of 414 patients met selection criteria (mean age 75 years, 53% male, mean Charlson score 2.5). Patients presented with gastrointestinal bleeding (58%), intracranial haemorrhage (38%) and other bleed types (4%). The INR of 67% of patients remained uncorrected at the last available test up to one day following receipt of FFP. In logistic regression analysis, the INR of patients who were older, those with a Charlson score of 4 or greater, and those with non-ICH bleeds (odds ratio vs. intracranial bleeding 0.48; 95% confidence interval 0.31–0.76) were more likely to remain uncorrected within one day following FFP administration. In an alternative definition of correction, (INR ≤1.5), 39% of patients’ INRs remained uncorrected. For a substantial proportion of patients, the INRs remain inadequately or uncorrected following FFP administration, with estimates varying depending on the INR threshold used.

Keywords

International normalised ratio - warfarin - haemorrhage - fresh frozen plasma - emergency medicine

• References

• 1 Pollock BE. Clinical experience with warfarin (coumadin) sodium, a new anticoagulant. J Am Med Assoc 1955; 159: 1094-1097.
• 2 Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-1419.
• 3 Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994 154. 1449-1457.
• 4 Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
• 5 Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124: 970-979.
• 6 Landefeld CS, Byeth RJ. Antigoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-328.
• 7 Palareti G, Leali N, Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.[comment]. Lancet 1996; 348: 423-428.
• 8 Wiedermann CJ, Stockner I. Warfarin-induced bleeding complications – clinical presentation and therapeutic options. Thromb Res 2008; 122 (Suppl. 02) S13-S18.
• 9 Goldstein JN, Thomas SH, Frontiero V. et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracer-ebral hemorrhage. Stroke 2006; 37: 151-155.
• 10 Huttner HB, Schellinger PD, Hartmann M. et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006; 37: 1465-1470.
• 11 Schulman S, Beyth RJ, Kearon C. et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (06) Suppl 257S-298S.
• 12 Boulanger L, Hauch O, Friedman M. et al. Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation. Ann Pharmacother 2006; 40: 1024-1029.
• 13 Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol 2006; 132: 277-285.
• 14 Russell MW, Joshi AV, Neumann PJ. et al. Predictors of hospital length of stay and cost in patients with intracerebral hemorrhage. Neurology 2006; 67: 1279-1281.
• 15 Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 53: 337.
• 16 Rubin TA, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supra-therapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest Endosc 2003; 58: 369-373.
• 17 Steiner T, Kaste M, Forsting M. et al. Recommendations for the management of intracranial haemorrhage – part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 2006; 22: 294-316.
• 18 Institute for Clinical Systems Improvement. Health Care Guideline: Antithrombotic Therapy Supplement. ISCSI. 2010 April Available at: URL: http: //www.icsi.org/antithrombotic_therapy_supplement__guideline__14045/antithrombotic_therapy_supplement__guideline_.html AccessedDecember 15, 2010
• 19 Pernod G, Godier A, Gozalo C. et al. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res 2010; 126: e167-e174.
• 20 The use of oral anticoagulants (warfarin) in older people. AGS Clinical Practices Committee. American Geriatric Society. J Am Geriatr Soc. 2000 48. 224-227.
• 21 Baker RI, Coughlin PB, Gallus AS. et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 492-497.